Search Results - "Lawrence H. Boise"

Refine Results
  1. 1

    How I treat high-risk myeloma by Lonial, Sagar, Boise, Lawrence H., Kaufman, Jonathan

    Published in Blood (24-09-2015)
    “…The treatment of patients with myeloma has dramatically changed over the past decade due in part to the development of new agents and myeloma-specific targets…”
    Get full text
    Journal Article
  2. 2

    Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma by Barwick, Benjamin G, Gupta, Vikas A, Vertino, Paula M, Boise, Lawrence H

    Published in Frontiers in immunology (21-05-2019)
    “…B cell activation and differentiation yields plasma cells with high affinity antibodies to a given antigen in a time-frame that allows for host protection…”
    Get full text
    Journal Article
  3. 3

    Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma by Boise, Lawrence H, Shanmugam, Mala

    Published in Cancer research (Chicago, Ill.) (01-05-2019)
    “…Marlein and colleagues demonstrate in multiple myeloma, bone marrow stromal cells transfer mitochondria to myeloma cells to increase cellular respiration,…”
    Get full text
    Journal Article
  4. 4

    Multiple myeloma immunoglobulin lambda translocations portend poor prognosis by Barwick, Benjamin G., Neri, Paola, Bahlis, Nizar J., Nooka, Ajay K., Dhodapkar, Madhav V., Jaye, David L., Hofmeister, Craig C., Kaufman, Jonathan L., Gupta, Vikas A., Auclair, Daniel, Keats, Jonathan J., Lonial, Sagar, Vertino, Paula M., Boise, Lawrence H.

    Published in Nature communications (23-04-2019)
    “…Multiple myeloma is a malignancy of antibody-secreting plasma cells. Most patients benefit from current therapies, however, 20% of patients relapse or die…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8

    Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells by Obeng, Esther A., Carlson, Louise M., Gutman, Delia M., Harrington, William J., Lee, Kelvin P., Boise, Lawrence H.

    Published in Blood (15-06-2006)
    “…Multiple myeloma (MM) is an incurable plasma cell malignancy. The 26S proteasome inhibitor, bortezomib, selectively induces apoptosis in MM cells; however, the…”
    Get full text
    Journal Article
  9. 9

    MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma by Wang, Dongxue, Hashimoto, Hideharu, Zhang, Xing, Barwick, Benjamin G, Lonial, Sagar, Boise, Lawrence H, Vertino, Paula M, Cheng, Xiaodong

    Published in Nucleic acids research (17-03-2017)
    “…The oncogenic transcription factor MYC and its binding partner MAX regulate gene expression by binding to DNA at enhancer-box (E-box) elements 5΄-CACGTG-3΄. In…”
    Get full text
    Journal Article
  10. 10

    The Tao of myeloma by Boise, Lawrence H., Kaufman, Jonathan L., Bahlis, Nizar J., Lonial, Sagar, Lee, Kelvin P.

    Published in Blood (18-09-2014)
    “…Multiple myeloma is a plasma cell malignancy in which significant advances have been observed during the last 15 years. Our understanding of the disease has…”
    Get full text
    Journal Article
  11. 11
  12. 12

    MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells by Gu, Yanyan, Kaufman, Jonathan L., Bernal, Leon, Torre, Claire, Matulis, Shannon M., Harvey, R. Donald, Chen, Jing, Sun, Shi-Yong, Boise, Lawrence H., Lonial, Sagar

    Published in Blood (22-05-2014)
    “…The function and survival of normal and malignant plasma cells depends on the elaborately regulated ubiquitin proteasome system. Proteasome inhibitors such as…”
    Get full text
    Journal Article
  13. 13

    Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells by Rozanski, Cheryl H, Arens, Ramon, Carlson, Louise M, Nair, Jayakumar, Boise, Lawrence H, Chanan-Khan, Asher A, Schoenberger, Stephen P, Lee, Kelvin P

    Published in The Journal of experimental medicine (04-07-2011)
    “…Sustained long-term antibody levels are the cornerstone of protective immunity, yet it remains unclear how they are durably maintained. A predominant theory…”
    Get full text
    Journal Article
  14. 14

    CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma by Murray, Megan E., Gavile, Catherine M., Nair, Jayakumar R., Koorella, Chandana, Carlson, Louise M., Buac, Daniela, Utley, Adam, Chesi, Marta, Bergsagel, P. Leif, Boise, Lawrence H., Lee, Kelvin P.

    Published in Blood (12-06-2014)
    “…Chemotherapeutic resistance remains a significant hurdle in the treatment of multiple myeloma (MM) and is significantly mediated by interactions between MM…”
    Get full text
    Journal Article
  15. 15

    Phosphorylation alters Bim‐mediated Mcl‐1 stabilization and priming by Conage‐Pough, Jason E., Boise, Lawrence H.

    Published in The FEBS journal (01-07-2018)
    “…Mcl‐1 is a highly labile protein, subject to extensive post‐translational regulation. This distinguishes Mcl‐1 from other antiapoptotic proteins and…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Game of Bones: How Myeloma Manipulates Its Microenvironment by Moser-Katz, Tyler, Joseph, Nisha S, Dhodapkar, Madhav V, Lee, Kelvin P, Boise, Lawrence H

    Published in Frontiers in oncology (09-02-2021)
    “…Multiple myeloma is a clonal disease of long-lived plasma cells and is the second most common hematological cancer behind Non-Hodgkin's Lymphoma. Malignant…”
    Get full text
    Journal Article
  18. 18

    Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors by Neri, Paola, Ren, Li, Gratton, Kathy, Stebner, Erin, Johnson, Jordan, Klimowicz, Alexander, Duggan, Peter, Tassone, Pierfrancesco, Mansoor, Adnan, Stewart, Douglas A., Lonial, Sagar, Boise, Lawrence H., Bahlis, Nizar J.

    Published in Blood (08-12-2011)
    “…Chromosomal instability is a defining feature of clonal myeloma plasma cells that results in the perpetual accumulation of genomic aberrations. In addition to…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion by Neri, Paola, Ren, Li, Azab, Abdel Kareem, Brentnall, Matthew, Gratton, Kathy, Klimowicz, Alexander C., Lin, Charles, Duggan, Peter, Tassone, Pierfrancesco, Mansoor, Adnan, Stewart, Douglas A., Boise, Lawrence H., Ghobrial, Irene M., Bahlis, Nizar J.

    Published in Blood (09-06-2011)
    “…Integrin-β7 (ITGB7) mRNA is detected in multiple myeloma (MM) cells and its presence is correlated with MAF gene activation. Although the involvement of…”
    Get full text
    Journal Article